RBL2 and cystadenoma: This has been confirmed by Worley MJ et al. who evaluated the immunohistochemical Rb2/p130 expression in a series of benign, borderline (SBT), and malignant ovarian tumors (low-grade (LGSC) and high-grade (HGSC) serous carcinoma), demonstrating a significant decrease in Rb2/p130 expression during the progression from cystadenoma to SBT to LGSC.